Human Liver Models Market Size 2026-2030
The human liver models market size is valued to increase by USD 5.17 billion, at a CAGR of 21.3% from 2025 to 2030. Technological convergence of AI and bioengineering will drive the human liver models market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 40.3% growth during the forecast period.
- By Type - Liver organoids segment was valued at USD 1.47 billion in 2024
- By Application - ADME studies segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 6.77 billion
- Market Future Opportunities: USD 5.17 billion
- CAGR from 2025 to 2030 : 21.3%
Market Summary
- The human liver models market is undergoing a significant transformation, driven by the pressing need for more predictive and human-relevant preclinical tools. A major catalyst is the convergence of advanced tissue engineering with AI-driven drug discovery, which demands the high-quality, human-specific data that engineered liver models provide.
- This symbiotic relationship is accelerating the move away from traditional animal testing, further supported by regulatory tailwinds like the FDA Modernization Act 2.0. A key trend is the specialization of platforms, such as liver-on-a-chip and 3D microtissues, for evaluating advanced therapeutic modalities, including gene therapies and antibody-drug conjugates.
- For instance, a biotechnology firm can now use a microphysiological system to model lipid nanoparticle delivery and first-pass metabolism with greater accuracy. However, widespread adoption is tempered by the high implementation costs and technical complexity of these systems.
- The operational expertise required to run perfusion systems and ensure biological reproducibility presents a considerable barrier for smaller labs, highlighting an ongoing tension between innovation and accessibility. This dynamic shapes a market landscape where cutting-edge predictive toxicology and disease modelling capabilities are balanced against practical challenges of cost and scalability.
What will be the Size of the Human Liver Models Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Human Liver Models Market Segmented?
The human liver models industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Type
- Liver organoids
- Liver-on-a-chip
- 2D models
- 3D bioprinting
- Application
- ADME studies
- Toxicology testing
- Disease modelling
- Others
- End-user
- Pharmaceutical and biotechnology companies
- Contract research organizations
- Academic and research institutes
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Asia
- Rest of World (ROW)
- North America
By Type Insights
The liver organoids segment is estimated to witness significant growth during the forecast period.
The liver organoids segment is advancing through innovations that overcome previous logistical and functional limitations.
A critical development is the ability to maintain functional in vitro models using stem-cell-derived hepatocytes at ambient temperatures for up to two weeks, enabling global ambient temperature shipping and improving biological reproducibility across research sites.
This addresses a major bottleneck in preclinical drug development. These advanced organoids, which integrate non-parenchymal cells, are increasingly pivotal for complex disease modelling, particularly in fibrotic disease modeling, where recapitulating cellular crosstalk is essential.
The move towards dynamic cell culture within these organoids enhances their physiological relevance, making them a cornerstone for next-generation therapeutic evaluation.
The Liver organoids segment was valued at USD 1.47 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 40.3% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Human Liver Models Market Demand is Rising in North America Request Free Sample
North America is the primary engine of growth, contributing over 40% of the market's incremental expansion.
This dominance is cemented by a favorable regulatory climate in the United States, where the FDA's acceptance of new approach methodologies for preclinical drug development has de-risked adoption for pharmaceutical firms.
The qualification of organ-chip data for toxicology testing can reduce screening phases by up to 30%. Consequently, large contract research organizations have accelerated the integration of liver spheroid models and cryopreserved human hepatocytes for ADME studies.
This has led to a 40% increase in the adoption of advanced human liver models for regulatory validation.
The region's robust ecosystem, which combines technology innovators with a high concentration of pharmaceutical clients, ensures it remains at the forefront of both commercial adoption and technological innovation in predictive toxicology and the use of body-on-chip systems.
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
- The evolution of the global human liver models market 2026-2030 is increasingly defined by its application in highly specific and complex areas of drug development.
- The use of predictive toxicology using liver models has matured beyond general screening to incorporate nuanced in vitro models for DILI prediction, enabling drug developers to identify hepatotoxic liabilities with greater precision early in the pipeline. This proactive failure analysis can save multiples on downstream clinical trial expenses compared to traditional workflows.
- Concurrently, organ-on-chip for ADME studies are becoming standard for characterizing pharmacokinetic profiles, providing a dynamic and physiologically relevant alternative to static cultures. The sector is also seeing significant advances in biofabrication, with 3D bioprinted liver tissue constructs offering unparalleled architectural biomimicry.
- These sophisticated platforms are proving essential for assessing lipid nanoparticle mediated delivery, a critical step for validating next-generation mRNA vaccines and gene therapies. Furthermore, specialized models are being developed for modeling metabolic dysfunction associated steatohepatitis (MASH), addressing a massive unmet need in metabolic disease research and accelerating the search for effective treatments.
What are the key market drivers leading to the rise in the adoption of Human Liver Models Industry?
- The technological convergence of AI and bioengineering serves as a key market driver, transforming biological models into sources of digital insight for drug discovery.
- The market is driven by the convergence of AI with bioengineering, which transforms human-relevant in vitro systems into powerful data generation engines for drug discovery.
- Advances in 3D bioprinting and bioink formulation are central to this, enabling the automated fabrication of tissues for high-content screening.
- This synergy is creating a feedback loop where AI-driven design improves tissue engineering, while the resulting organ-on-a-chip technology provides clean, human-specific data to train machine learning algorithms.
- Innovations in perfusion systems are also lowering barriers to entry, with new platforms reducing experiment setup times by 30%.
- This makes it easier for labs to adopt sophisticated multi-organ systems and move beyond the limitations of older models that struggled to maintain long-term cytochrome P450 metabolism.
What are the market trends shaping the Human Liver Models Industry?
- A key market trend involves the optimization of models for advanced therapeutics and genetic medicines. This reflects a shift toward specialized platforms for novel drug modalities.
- A significant trend is the adaptation of models for advanced therapeutic modalities. Platforms are being optimized for gene therapy validation and for assessing RNA interference drugs, where predicting the efficacy of lipid nanoparticle delivery is critical. Unlike traditional cell-based assays, new systems can replicate physiological flow, improving predictive accuracy for mRNA uptake by over 40% compared to static cultures.
- This allows for more effective hepatotoxicity screening and characterization of large-molecule drugs. The development of 3D microtissues and scaffold-free tissue with complex hepatic tissue microarchitecture is enabling researchers to create more accurate representations of human liver biology, which is essential for testing these next-generation treatments.
What challenges does the Human Liver Models Industry face during its growth?
- The high cost and technical complexity associated with implementation remain a key challenge, affecting the broader adoption of advanced systems.
- High implementation costs and technical complexity are significant challenges, as the capital expenditure for a microphysiological system or liver-on-a-chip platform can be up to 10 times higher than for traditional 2D models. This barrier is particularly acute for smaller labs, which may lack the resources and multidisciplinary expertise for high-throughput screening.
- Operating these systems often involves a steep learning curve, which can increase technician onboarding time by over 60%. While innovations are simplifying workflows for applications like drug-induced liver injury analysis, the field must continue to address issues of cost and usability to broaden adoption.
- Ensuring long-term metabolic competency and achieving the goals of new approach methodologies for predictive toxicology remain difficult without more accessible and standardized platforms.
Exclusive Technavio Analysis on Customer Landscape
The human liver models market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the human liver models market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Human Liver Models Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, human liver models market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
ATCC - Supplies credible biological products and advanced model systems, including HepG2 and primary hepatocyte cells, crucial for complex liver research and development applications.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- ATCC
- BioIVT LLC
- Biopredic Advancells Pvt. Ltd.
- CELLINK AB
- CN Bio Innovations Ltd.
- Corning Inc.
- Cyfuse Biomedical K.K.
- Emulate Inc.
- InSphero AG
- Kirkstall Ltd.
- Merck KGaA
- MIMETAS BV
- Organovo Holdings Inc.
- Pandorum Technologies Pvt. Ltd.
- PhoenixBio Co., Ltd.
- Promega Corp.
- STEMCELL Technologies Inc.
- Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Human liver models market
- In September 2024, Emulate Inc. had its Liver-Chip accepted into the United States Food and Drug Administration's (FDA) Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program, marking a key step toward the qualification of organ-on-chip technology for regulatory submissions.
- In February 2025, BICO Group launched a specialized high-resolution bioink kit designed to replicate the specific stiffness and microarchitecture of hepatic tissue, addressing a significant technical barrier in 3D bioprinting.
- In April 2025, Organovo Holdings Inc. completed its strategic rebranding to VivoSim Labs, Inc., signaling a renewed focus on commercializing its 3D bioprinting platform for predictive toxicology in the US market.
- In May 2025, Labcorp announced the expansion of its non-clinical safety portfolio to include a comprehensive suite of 3D human liver spheroid assays, standardizing these advanced models for industrial-scale safety testing.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Human Liver Models Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 296 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 21.3% |
| Market growth 2026-2030 | USD 5168.6 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 18.9% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, China, Japan, India, South Korea, Singapore, Indonesia, Brazil, Saudi Arabia, South Africa, UAE, Argentina, Australia, Chile and Turkey |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
- The human liver models market is built upon a spectrum of technologies, ranging from established 2d models and cell-based assays using primary human hepatocytes to advanced functional in vitro models. Innovations in liver organoids and liver-on-a-chip platforms, which utilize stem-cell-derived hepatocytes and non-parenchymal cells, are setting new standards.
- The integration of perfusion systems and scaffold-free tissue techniques in these microphysiological system setups enhances metabolic competency, crucial for adme studies and disease modelling. Concurrently, 3d bioprinting, enabled by sophisticated bioink formulation, allows for precise reconstruction of hepatic tissue microarchitecture, creating superior 3d microtissues. These advancements are pivotal for high-content screening and hepatotoxicity screening.
- For boardroom-level strategy, the decision to invest in these platforms for predictive toxicology is critical, as they can de-risk the development of novel therapeutics. For example, validating a new gene therapy using these models can deliver up to a 90% accuracy rate in predicting liver-related adverse events, directly influencing R&D budget allocation and pipeline prioritization.
What are the Key Data Covered in this Human Liver Models Market Research and Growth Report?
-
What is the expected growth of the Human Liver Models Market between 2026 and 2030?
-
USD 5.17 billion, at a CAGR of 21.3%
-
-
What segmentation does the market report cover?
-
The report is segmented by Type (Liver organoids, Liver-on-a-chip, 2D models, and 3D bioprinting), Application (ADME studies, Toxicology testing, Disease modelling, and Others), End-user (Pharmaceutical and biotechnology companies, Contract research organizations, and Academic and research institutes) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Technological convergence of AI and bioengineering, High cost and technical complexity of implementation
-
-
Who are the major players in the Human Liver Models Market?
-
ATCC, BioIVT LLC, Biopredic Advancells Pvt. Ltd., CELLINK AB, CN Bio Innovations Ltd., Corning Inc., Cyfuse Biomedical K.K., Emulate Inc., InSphero AG, Kirkstall Ltd., Merck KGaA, MIMETAS BV, Organovo Holdings Inc., Pandorum Technologies Pvt. Ltd., PhoenixBio Co., Ltd., Promega Corp., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.
-
Market Research Insights
- The market is shaped by a definitive shift toward human-relevant in vitro systems, as their adoption for preclinical drug development has been shown to improve prediction of drug-induced liver injury by over 30% compared to legacy methods. This transition is propelled by the formalization of new approach methodologies (NAMs) in regulatory frameworks, diminishing reliance on animal models.
- Organ-on-chip technology now facilitates complex evaluations, such as first-pass metabolism simulation and pharmacokinetic profiling. Furthermore, the use of patient-derived organoids in high-throughput screening campaigns allows for testing against diverse genetic backgrounds, with some platforms demonstrating a twofold increase in the identification of responder versus non-responder populations for developmental drugs, directly impacting clinical trial design and cost.
We can help! Our analysts can customize this human liver models market research report to meet your requirements.